Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an announcement.

Sihuan Pharmaceutical Holdings Group announced that its non-wholly-owned subsidiary, Xuanzhu Biopharmaceutical, has received approval from the Hong Kong Stock Exchange for the listing and dealing of 357,245,794 H shares converted from previously unlisted shares, subject to remaining conditions. The move advances H share full circulation for Xuanzhu, potentially enhancing its liquidity, investor base and capital-market profile, and reflects Sihuan’s broader strategy to strengthen its innovative biopharmaceutical platform alongside its medical aesthetics business.

Xuanzhu Biopharm, listed in Hong Kong since October 2025, focuses on R&D, production and commercialization of class 1 innovative drugs targeting major diseases such as digestive disorders, oncology and non-alcoholic steatohepatitis. With dual small-molecule and large-molecule platforms spanning biopharmaceuticals and antibody-drug conjugates, Xuanzhu’s expanded market access may reinforce Sihuan’s competitive positioning in China’s innovation-driven pharma sector and support long-term pipeline development.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group is an international medical aesthetics and pharmaceutical company founded in 2001 and listed in Hong Kong since 2010. The group operates an innovation-led model with an independent R&D platform, broad global product pipeline, full-spectrum dosage form production, strong registration capabilities and a mature nationwide sales network, aiming to be a leading medical aesthetics and biopharmaceutical player in China through its dual-engine strategy.

Average Trading Volume: 35,639,862

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$13.53B

For an in-depth examination of 0460 stock, go to TipRanks’ Overview page.